Posted by Michael Wonder on 04 Feb 2017
Most important breast cancer drug in two decades will not get NHS funding
3 February 2017 - A new drug described as one of the "most important" advances in treating breast cancer in two decades will not be approved on the NHS, under rationing plans.
Around 6,000 women a year, many with terminal disease, could benefit from palbociclib.
The treatment has been found to stall tumours by 10 months - almost twice as long as standard drugs.
